Insights

Insights From Our Experts

Articles

Insights from BIO with OS Therapies

At this year’s BIO International Convention 2025, pharmaphorum’s Jonah Comstock sat down with Paul Romness, CEO of OS Therapies, and Farah Ahmad, VP of Business Development at EVERSANA, to explore how emerging biotech companies are navigating…

Case Study: Transforming Market Access with NAVLIN Insights KPI

How one global pharma team turned fragmented pricing data into strategic power. In a complex launch environment, pricing and market access teams face mounting pressure to deliver insights that resonate with CEOs, affiliates, payers, and investors.…

Pharmatizing AI & EVERSANA’s Bold Vision for Its AI Accelerator

EVERSANA continues to redefine the future of pharmaceutical commercialization with its newly launched AI Accelerator—a dedicated center of excellence designed to embed artificial intelligence across every touchpoint of the life sciences value chain.  Spearheaded by Chief…

Empowering Scientific Dialogue: Key Takeaways from the FDA’s SIUU Guidance
Empowering Scientific Dialogue: Key Takeaways from the FDA’s SIUU Guidance

Discover the latest insights from the FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU). This comprehensive document provides a clarified framework for pharmaceutical companies to share scientifically sound information with healthcare providers. In this…

Bridging the Evidence Gap in Hereditary Angioedema (HAE): Indirect Comparison Highlights Garadacimab’s Potential

Hereditary angioedema (HAE) is a rare, debilitating condition marked by unpredictable and potentially life-threatening swelling episodes. While long-term prophylactic therapies have significantly improved disease management, selecting the optimal treatment remains complex—particularly in the absence of direct…

Where Process Meets Profit: How Strategic Order to Cash Drives Real Revenue Outcomes

Is your Order to Cash (OTC) process helping you maximize revenue—or quietly leaking it? In their latest article, EVERSANA experts Christina Christos and Jim Burke explore how pharmaceutical manufacturers can align OTC and Revenue Management to…

Reimagining Patient Health Experiences: A New Paradigm for Transforming Lives

Traditionally, the healthcare system has approached patient care, especially for those with acute conditions and rare diseases, through a lens of sympathy, problem-solving, and normalization. The focus has often been on identifying deficits and developing tools…

Comparing Long-Term HAE Treatments: Insights from a Robust Network Meta-Analysis

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent edema attacks in various parts of the body, including the extremities, face, gastrointestinal tract, and airway. While most current treatments can help relieve acute symptoms…

Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency

In an EVERSANA-led discussion, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key Challenges: 3x lower net revenue…

Navigating the Final FDA SIUU Guidance: Strategic Considerations for Scientific Exchange at ASCO and Other Congresses

The FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU) marks a pivotal shift for pharmaceutical companies—offering new clarity and flexibility for engaging healthcare providers in compliant, science-based dialogue. In this POV, EVERSANA ONCOLOGY’s experts…